鼻腔鼻窦内翻性乳头状瘤恶变患者的临床特征和预后因素分析  

Analysis of the clinical features and prognostic factors of patients with sinonasal inverted papilloma

作　　者：周晖[1] 李红艳[1] 倪富强[1] 郭鸿[1] 

机构地区：[1]北京天坛医院,北京100050

出　　处：《中国肿瘤临床与康复》2014年第11期1325-1327,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨鼻腔鼻窦内翻性乳头状瘤（SNIP）恶变患者的临床特征,分析影响预后的因素。方法选取2009年5月至2013年5月间收治的伴有恶变症状的SNIP患者15例,分析SNIP恶变患者的临床特征、治疗方式及效果,统计影响患者预后的主要因素。结果 15例患者均获随访,随访时间为13~58个月,中位随访时间23个月;生存时间8~95个月,中位生存期为60.6个月。15例SNIP恶变患者中,接受单一方法治疗患者的5年生存率为40.0%（2/5）,接受综合方法治疗患者的5年生存率为90.0%（9/10）,两组差异有统计学意义（P〈0.05）。Logistic回归分析结果表明,临床分期、远处转移及治疗方式是影响SNIP预后的独立危险因素（均P〈0.05）。结论 SNIP恶变率较低,但缺乏特异性,临床分期、远处转移及治疗方式是影响患者预后的独立危险因素,临床应采取综合治疗方法改善患者的预后。Objective To investigate the the clinical features and prognostic factors of patients with sinonasal inverted papilloma（SNIP）.Methods 15 SNIP patients with malignant symptoms in Beijing Tiantan Hospital from May 2009 to May 2013 were chosen for the study.The clinical characteristics,treatment and effects and the main factors affecting the prognosis of patients were ananlyzed.Results All the 15 patients were followed up and the follow-up time was 13 ~ 58 mo,the median follow-up time was 23 mo.The survival period was 8 ~ 95 mo and the median survival period was 60.6 mo.The 5-year survival rate of patients who received single treatmen was 40.0%（2 /5）,while it was 90.0%（9 /10） of those who received integrated treatment and there was significant difference between two groups（P 〈 0.05）.The Logistic regression analysis showed that clinical stag（95% CI：0.231-0.446,P 〈 0.05）,distant metastasis（95% CI：0.326-0.546,P 〈 0.05） and treatment（95% CI：0.534-0.657,P 〈 0.05） were the independent risk factors of prognosis of SNIP treatment（P 〈 0.05）.Conclusion The canceration rate SNIP is low,but it is lack of specificity.The clinical stage,distant metastasisand treatment are the independent risk factors of prognosisof clinical patients,we should take comprehensive treatment to improve the prognosis of patients.

关 键 词：鼻腔鼻窦内翻性乳头状瘤 临床特征 病理特征 预后 

分 类 号：R739.62[医药卫生—肿瘤]